.jpg)
MedTech (R)evolution
Panel Session
Christian Haller
CEO and Founder
LifeLine Medical
David Curd, MS
Vice President, Clinical Affairs
Avanos
John Marler
Clinical Team Leader, Division of Neurology Products
U.S. Food and Drug Administration
Jamie Wolszon
Associate Vice President, Technology & Regulatory Affairs
AdvaMed
Stephanie Fertig
Director, NINDS Small Business Programs
National Institute of Neurological Disorders and Stroke, NIH
The addiction crisis results in 142,000 preventable deaths in the US annually, with an associated cost of $340 billion. Of the 21.7 million Americans who should receive treatment in 2017, only 2.5 million went to treatment. Approximately 75% of those who do receive treatment do not complete it. Recidivism rates are about 80%. Managing the supply of illegal drugs historically is not impactful, and the majority of deaths are due to legal access (19,000 annual deaths are due to prescription opioids and 88,000 deaths are due to alcohol). Addiction represents one of the largest categories of preventable deaths. The panel explores how mobile health, medical devices and digital therapeutics may have a unique role to both improve access to treatment and avoid unnecessary deaths. The panel will explore market, policy and clinical issues related to opioid addiction and the role of mobile health, medical devices and digital therapeutics in its treatment.
